Bioavailability of Telmisartan/Amlodipine FDC vs Mono-components

Phase 1, randomised, open-label trial of telmisartan and amlodipine in hypertension (HTN) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point up to 144 hours and Maximum measured concentration of the analyte in plasma up to 144 hours. Started Jul 2007; status: completed.